Delanzomib, a Novel Proteasome Inhibitor, Combined With Adalimumab Drastically Ameliorates Collagen-Induced Arthritis in Rats by Improving and Prolonging the Anti-TNF-α Effect of Adalimumab

Delanzomib is a novel proteasome inhibitor initially developed for treating multiple myeloma. It was found to inhibit the expression of tumor necrosis factor alpha (TNF-α). This study aimed to investigate the ameliorating effect of delanzomib on collagen-induced arthritis (CIA) and to explore the ph...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Lei Wang, Lixiong Liu, Xiaoping Hong, Dongzhou Liu, Zeneng Cheng
Formato: article
Lenguaje:EN
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://doaj.org/article/6f2be6b297544562aa8bee1dad59baca
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:6f2be6b297544562aa8bee1dad59baca
record_format dspace
spelling oai:doaj.org-article:6f2be6b297544562aa8bee1dad59baca2021-11-22T06:06:37ZDelanzomib, a Novel Proteasome Inhibitor, Combined With Adalimumab Drastically Ameliorates Collagen-Induced Arthritis in Rats by Improving and Prolonging the Anti-TNF-α Effect of Adalimumab1663-981210.3389/fphar.2021.782385https://doaj.org/article/6f2be6b297544562aa8bee1dad59baca2021-11-01T00:00:00Zhttps://www.frontiersin.org/articles/10.3389/fphar.2021.782385/fullhttps://doaj.org/toc/1663-9812Delanzomib is a novel proteasome inhibitor initially developed for treating multiple myeloma. It was found to inhibit the expression of tumor necrosis factor alpha (TNF-α). This study aimed to investigate the ameliorating effect of delanzomib on collagen-induced arthritis (CIA) and to explore the pharmacodynamics and pharmacokinetics (PK) interactions between delanzomib and adalimumab. Rats with CIA were randomly assigned to receive the treatment with delanzomib, adalimumab, delanzomib combined with adalimumab, or placebo. Visual inspection and biochemical examinations including TNF-α, interleukin 6, and C-reactive protein were performed to assess arthritis severity during the treatment. The adalimumab concentration in rats was determined to evaluate the PK interaction between delanzomib and adalimumab. Also, the levels of neonatal Fc receptor (FcRn) and FcRn mRNA were measured to explore the role of FcRn in the PK interaction between delanzomib and adalimumab. As a result, delanzomib combined with adalimumab exhibited stronger anti-arthritis activity than a single drug because both drugs synergistically reduced TNF-α level in vivo. Delanzomib also decreased adalimumab elimination in rats by increasing the level of FcRn. The slower elimination of adalimumab in rats further prolonged the anti-TNF-α effect of adalimumab. Moreover, FcRn level was increased by delanzomib via suppressing FcRn degradation rather than promoting FcRn production. In conclusion, delanzomib combined with adalimumab may be a potential therapeutic approach for treating rheumatoid arthritis. The initial finding that the PK interaction occurred between delanzomib and adalimumab may have clinical relevance for patients who simultaneously take proteasome inhibitors and anti-TNF-α therapeutic proteins.Lei WangLei WangLixiong LiuXiaoping HongDongzhou LiuZeneng ChengFrontiers Media S.A.articleadalimumabcollagen-induced arthritisdelanzomibneonatal Fc receptorpharmacokineticsTherapeutics. PharmacologyRM1-950ENFrontiers in Pharmacology, Vol 12 (2021)
institution DOAJ
collection DOAJ
language EN
topic adalimumab
collagen-induced arthritis
delanzomib
neonatal Fc receptor
pharmacokinetics
Therapeutics. Pharmacology
RM1-950
spellingShingle adalimumab
collagen-induced arthritis
delanzomib
neonatal Fc receptor
pharmacokinetics
Therapeutics. Pharmacology
RM1-950
Lei Wang
Lei Wang
Lixiong Liu
Xiaoping Hong
Dongzhou Liu
Zeneng Cheng
Delanzomib, a Novel Proteasome Inhibitor, Combined With Adalimumab Drastically Ameliorates Collagen-Induced Arthritis in Rats by Improving and Prolonging the Anti-TNF-α Effect of Adalimumab
description Delanzomib is a novel proteasome inhibitor initially developed for treating multiple myeloma. It was found to inhibit the expression of tumor necrosis factor alpha (TNF-α). This study aimed to investigate the ameliorating effect of delanzomib on collagen-induced arthritis (CIA) and to explore the pharmacodynamics and pharmacokinetics (PK) interactions between delanzomib and adalimumab. Rats with CIA were randomly assigned to receive the treatment with delanzomib, adalimumab, delanzomib combined with adalimumab, or placebo. Visual inspection and biochemical examinations including TNF-α, interleukin 6, and C-reactive protein were performed to assess arthritis severity during the treatment. The adalimumab concentration in rats was determined to evaluate the PK interaction between delanzomib and adalimumab. Also, the levels of neonatal Fc receptor (FcRn) and FcRn mRNA were measured to explore the role of FcRn in the PK interaction between delanzomib and adalimumab. As a result, delanzomib combined with adalimumab exhibited stronger anti-arthritis activity than a single drug because both drugs synergistically reduced TNF-α level in vivo. Delanzomib also decreased adalimumab elimination in rats by increasing the level of FcRn. The slower elimination of adalimumab in rats further prolonged the anti-TNF-α effect of adalimumab. Moreover, FcRn level was increased by delanzomib via suppressing FcRn degradation rather than promoting FcRn production. In conclusion, delanzomib combined with adalimumab may be a potential therapeutic approach for treating rheumatoid arthritis. The initial finding that the PK interaction occurred between delanzomib and adalimumab may have clinical relevance for patients who simultaneously take proteasome inhibitors and anti-TNF-α therapeutic proteins.
format article
author Lei Wang
Lei Wang
Lixiong Liu
Xiaoping Hong
Dongzhou Liu
Zeneng Cheng
author_facet Lei Wang
Lei Wang
Lixiong Liu
Xiaoping Hong
Dongzhou Liu
Zeneng Cheng
author_sort Lei Wang
title Delanzomib, a Novel Proteasome Inhibitor, Combined With Adalimumab Drastically Ameliorates Collagen-Induced Arthritis in Rats by Improving and Prolonging the Anti-TNF-α Effect of Adalimumab
title_short Delanzomib, a Novel Proteasome Inhibitor, Combined With Adalimumab Drastically Ameliorates Collagen-Induced Arthritis in Rats by Improving and Prolonging the Anti-TNF-α Effect of Adalimumab
title_full Delanzomib, a Novel Proteasome Inhibitor, Combined With Adalimumab Drastically Ameliorates Collagen-Induced Arthritis in Rats by Improving and Prolonging the Anti-TNF-α Effect of Adalimumab
title_fullStr Delanzomib, a Novel Proteasome Inhibitor, Combined With Adalimumab Drastically Ameliorates Collagen-Induced Arthritis in Rats by Improving and Prolonging the Anti-TNF-α Effect of Adalimumab
title_full_unstemmed Delanzomib, a Novel Proteasome Inhibitor, Combined With Adalimumab Drastically Ameliorates Collagen-Induced Arthritis in Rats by Improving and Prolonging the Anti-TNF-α Effect of Adalimumab
title_sort delanzomib, a novel proteasome inhibitor, combined with adalimumab drastically ameliorates collagen-induced arthritis in rats by improving and prolonging the anti-tnf-α effect of adalimumab
publisher Frontiers Media S.A.
publishDate 2021
url https://doaj.org/article/6f2be6b297544562aa8bee1dad59baca
work_keys_str_mv AT leiwang delanzomibanovelproteasomeinhibitorcombinedwithadalimumabdrasticallyamelioratescollageninducedarthritisinratsbyimprovingandprolongingtheantitnfaeffectofadalimumab
AT leiwang delanzomibanovelproteasomeinhibitorcombinedwithadalimumabdrasticallyamelioratescollageninducedarthritisinratsbyimprovingandprolongingtheantitnfaeffectofadalimumab
AT lixiongliu delanzomibanovelproteasomeinhibitorcombinedwithadalimumabdrasticallyamelioratescollageninducedarthritisinratsbyimprovingandprolongingtheantitnfaeffectofadalimumab
AT xiaopinghong delanzomibanovelproteasomeinhibitorcombinedwithadalimumabdrasticallyamelioratescollageninducedarthritisinratsbyimprovingandprolongingtheantitnfaeffectofadalimumab
AT dongzhouliu delanzomibanovelproteasomeinhibitorcombinedwithadalimumabdrasticallyamelioratescollageninducedarthritisinratsbyimprovingandprolongingtheantitnfaeffectofadalimumab
AT zenengcheng delanzomibanovelproteasomeinhibitorcombinedwithadalimumabdrasticallyamelioratescollageninducedarthritisinratsbyimprovingandprolongingtheantitnfaeffectofadalimumab
_version_ 1718418108219129856